Yet another Class I ACCF/AHA for AstraZeneca's Brilinta
This article was originally published in Scrip
Executive Summary
The American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) have updated their guidelines to include a Class I recommendation for AstraZeneca's Brilinta (ticagrelor) in patients with ST-elevation myocardial infarction (STEMI).